Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer
- PMID: 20135344
- PMCID: PMC2903659
- DOI: 10.1007/s10549-010-0769-3
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer
Abstract
Given the greatly elevated risks of contralateral breast cancer (CBC) observed in breast cancer patients who carry mutations in BRCA1 and BRCA2, it is critical to determine the effectiveness of standard adjuvant therapies in preventing CBC in mutation carriers. The WECARE study is a matched, case-control study of 708 women with CBC as cases and 1,399 women with unilateral breast cancer (UBC) as controls, including 181 BRCA1/BRCA2 mutation carriers. Interviews and medical record reviews provided detailed information on risk factors and breast cancer therapy. All study participants were screened for BRCA1 and BRCA2 mutations using denaturing high-performance liquid chromatography (DHPLC) to detect genetic variants in the coding and flanking regions of the genes. Conditional logistic regression was used to compare the risk of CBC associated with chemotherapy and tamoxifen in BRCA1/BRCA2 mutation carriers and non-carriers. Chemotherapy was associated with lower CBC risk both in non-carriers (RR = 0.6 [95% CI: 0.5-0.7]) and carriers (RR = 0.5 [95% CI: 0.2-1.0]; P value = 0.04). Tamoxifen was associated with a reduced CBC risk in non-carriers (RR = 0.7 [95% CI: 0.6-1.0]; P value = 0.03). We observed a similar but non-significant reduction associated with tamoxifen in mutation carriers (RR = 0.7 [95% CI: 0.3-1.8]). The tests of heterogeneity comparing carriers to non-carriers did not provide evidence for a difference in the associations with chemotherapy (P value = 0.51) nor with tamoxifen (P value = 0.15). Overall, we did not observe a difference in the relative risk reduction associated with adjuvant treatment between BRCA1/BRCA2 mutation carriers and non-carriers. However, given the higher absolute CBC risk in mutation carriers, the potentially greater impact of adjuvant therapy in reducing CBC risk among mutation carriers should be considered when developing treatment plans for these patients.
Similar articles
-
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.Eur J Cancer. 2013 Sep;49(14):2979-85. doi: 10.1016/j.ejca.2013.04.028. Epub 2013 May 21. Eur J Cancer. 2013. PMID: 23706288 Free PMC article.
-
Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2.J Clin Oncol. 2010 May 10;28(14):2404-10. doi: 10.1200/JCO.2009.24.2495. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368571 Free PMC article.
-
Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.Breast Cancer. 2015 Jul;22(4):327-34. doi: 10.1007/s12282-015-0619-6. Epub 2015 May 30. Breast Cancer. 2015. PMID: 26022977
-
Breast cancer treatment in mutation carriers: surgical treatment.Minerva Ginecol. 2016 Oct;68(5):548-56. Epub 2016 Jan 28. Minerva Ginecol. 2016. PMID: 26822896 Review.
-
Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.Fam Cancer. 2023 Jul;22(3):283-289. doi: 10.1007/s10689-023-00331-6. Epub 2023 Apr 29. Fam Cancer. 2023. PMID: 37119509 Free PMC article. Review.
Cited by
-
Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers.Breast Cancer Res Treat. 2017 Apr;162(2):353-364. doi: 10.1007/s10549-017-4117-8. Epub 2017 Jan 28. Breast Cancer Res Treat. 2017. PMID: 28132393 Free PMC article.
-
Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.Cancer Causes Control. 2013 Aug;24(8):1605-14. doi: 10.1007/s10552-013-0237-6. Epub 2013 Jun 18. Cancer Causes Control. 2013. PMID: 23775025 Free PMC article.
-
Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.Breast Cancer Res. 2016 Jul 12;18(1):65. doi: 10.1186/s13058-016-0726-0. Breast Cancer Res. 2016. PMID: 27400983 Free PMC article.
-
Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer.Curr Breast Cancer Rep. 2011 Sep 1;3(3):151-155. doi: 10.1007/s12609-011-0047-3. Curr Breast Cancer Rep. 2011. PMID: 24587872 Free PMC article.
-
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.Cancer Prev Res (Phila). 2014 Jul;7(7):698-707. doi: 10.1158/1940-6207.CAPR-14-0047. Epub 2014 May 9. Cancer Prev Res (Phila). 2014. PMID: 24817481 Free PMC article.
References
-
- Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–1130. - PMC - PubMed
-
- Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, Breast Cancer Linkage Consortium Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676–89. - PMC - PubMed
-
- Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700–710. - PMC - PubMed
-
- Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, Haas B, Norton L, Offit K. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res. 1998;58(9):1839–1842. - PubMed
-
- Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401–1408. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous